2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2204 Single-cell immune profiling reveals distinct baseline immune features associated with deep clinical responses to dara-rvd in patients with high-risk smoldering multiple myeloma

Nayda Bidikian, MD, Francesco Corrado, MD2, Michelle Aranha, PhD3, Kevin Cabrera4, Rosa Toenges, MD5, Jean-Baptiste Alberge, PhD6, Lorena Pantano7, Ting Wu, PhD8, Sophie Magidson, BS9, Katherine Towle10, Tarek Mouhieddine, MD11, Gaddy Getz, PhD12, Omar Nadeem, MD13, Irene M Ghobrial, MD14
1 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, United States, Yale New Haven Hospital, New Haven, Connecticut, United States
2 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, United States
3 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, United States
4 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, United States
5 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, United States
6 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, United States
7 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
8 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
9 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, United States
10 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Harvard Medical School, Boston, United States, Krantz Family Center for Cancer Research, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, United States

INTRODUCTION

Daratumumab (Dara) has demonstrated remarkable clinical activity, both as monotherapy and as part of combination regimens in patients across different stages of multiple myeloma (MM). Beyond its direct anti-tumor activity, Dara containing regimens exert immunomodulatory effects through targeting CD38-expressing immune cells as well as through the additional immunomodulatory effects of combination agents such as bortezomib, lenalidomide, and dexamethasone (RVD). However, the immune correlates of response to Dara-RVD have not been defined in patients with high-risk smoldering MM (HR-SMM). We hypothesized that baseline immune composition is associated with depth of response to Dara-RVD. We therefore performed single-cell RNA and T-cell receptor (TCR) sequencing on peripheral blood (PB) and bone marrow (BM) samples from patients with HR-SMM treated with Dara-RVD.

METHODS

We performed single-cell RNA and TCR sequencing on 42 samples collected from 33 patients with HR-SMM treated with Dara-RVD. Specifically, we included samples from patients who achieved complete response (CR; n = 24) and those who did not achieve CR (non-CR; n = 9). Patients with HR-SMM were enrolled in the phase II B-PRISM study (NCT04775550). To validate our findings, an independent scRNA-seq dataset was incorporated from the phase II D-PRISM study (NCT03236428). Specifically, we included data from patients with SMM treated with Dara monotherapy (n = 34), including those achieving very good partial response (VGPR) or better (n = 7) and those achieving <VGPR (n = 27). Single-cell gene expression and TCR libraries were prepared with the Chromium Single Cell 5' kit. Overall, we profiled 215,724 cells, comprising monocytes, natural killer (NK) cells, T cells, dendritic cells, B cells, and plasma cells.

RESULTS

To identify baseline immune features associated with response, we first characterized the NK cell compartment. We identified three distinct NK cell subsets: CD56dim, CD56bright, and adaptive NK cells defined by higher expression of CD2, ZBTB38, and KLRC2 and lower expression of FCER1G and CD38. Patients who achieved CR showed a higher proportion of adaptive NK cells at baseline compared with non-CR (two-sided Wilcoxon rank-sum test, q = 0.061). Longitudinal profiling demonstrated selective depletion of CD56dim NK cells (median 75% versus 11%, q = 0.001), with relative preservation of the adaptive NK subset, suggesting reduced susceptibility to Dara-induced fratricide and a potential role in sustaining Dara-mediated effector activity.

To investigate whether baseline NK-cell composition predicts response to Dara monotherapy as well, we derived an adaptive NK signature from the top 10 differentially expressed genes in this subset and applied it to an independent cohort of patients with SMM treated with Dara monotherapy. Patients achieving VGPR or better after Dara showed significant enrichment of this signature compared with patients achieving <VGPR (one-sided Wilcoxon rank-sum test, p = 0.037), validating baseline adaptive NK-cell enrichment as a correlate of response to Dara-containing regimens.
Extending our analysis in the Dara-RVD cohort to other immune cells, T cells from patients achieving CR showed baseline enrichment of cytotoxic effector T cells such as CD4+ cytotoxic T lymphocytes (CTLs) (median 3.5% versus 1.3%; q = 0.019) and CD8+GZMB+T-effector memory (TEM) cells (median 10.0% vs. 3.6%, q=0.053) compared with non-CR. These cytotoxic subsets exhibited the highest proportion of clonally expanded T cells, suggesting they may represent tumor-reactive cells primed for further activation following Dara-RVD mediated depletion of CD38-expressing immunosuppressive cells.

CONCLUSION

Single-cell immune profiling identified baseline immune features associated with complete response to Dara-RVD in patients with HR-SMM, including the enrichment of adaptive NK cells and cytotoxic T cells. These findings suggest that a favorable baseline immune landscape may be further shaped by Dara-RVD, contributing to deeper clinical responses. Together, these findings highlight the potential of baseline immune features as a promising biomarker strategy to inform treatment selection and enable personalized treatment approaches, especially as the therapeutic landscape for SMM continues to evolve.

Nayda Bidikian, MD: No relevant conflicts of interest to declare.